Amgen Inc. urged a federal judge to overturn a jury’s $50.3 million verdict for its leukemia drug Blincyto’s infringement of ...

The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, ...

according to Amgen. The drug was given as a subcutaneous injection every four weeks in the study, and showed a clear dose response with a 7.2% weight loss in the lowest dose group (140 mg ...

The next drug Amgen brought to market in 1991 was Neupogen, a recombinant version of G-CSF (granulocyte colony-stimulating factor), that could be used to treat chemotherapy-induced neutropenia in ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

Amgen said it has started two critical late-stage trials for its experimental weight loss injection, MariTide, another step in its bid to enter the booming obesity drug market. MariTide is a ...